Benefit-Risk Of arterial THrombotic prEvention with Rivaroxaban for atrial fibrillation in daily clinical practice. A French cohort within the nationwide claims and hospital database (BROTHER).

02/08/2016
23/04/2024
EU PAS number:
EUPAS14567
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

BROTHER_ENCePP_Protocol_V1.0_20181203

English (7.17 MB - PDF) View document
Study results
Study results

BROTHER_Study_report_1-year_follow-up_V3.0_Clean_20181120

English (3.88 MB - PDF) View document

BROTHER_Study_report_2-year_follow-up_V1.0clean_20181116

English (4.5 MB - PDF) View document
Study report
Other information
Publications
Study publications
Blin P, Fauchier L, Dureau-Pournin C, Sacher F, Dallongeville J, Bernard MA, La…